Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6X70G)

• Drug Name: ABI-H2158 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis B	1E51	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM6X70G

Molecule-Related Drug Atlas

Drug(s) Targeting Hepatitis B virus Capsid protein (HBV C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JNJ-56136379	DM9RW6H	Hepatitis B	1E51	Phase 2	[3]
ABI-H0731	DMX1KDM	Hepatitis B	1E51	Phase 2	[4]
ABI-H3733	DM4TN6W	Hepatitis B	1E51	Phase 1	[2]
EDP-514	DM8KRA3	Chronic HBV infection	1E51.0Z	Phase 1	[5]
RG7907	DMKVIS5	Hepatitis B	1E51	Phase 1	[6]
ZM-H1505R	DMX6AJ8	Hepatitis B	1E51	Phase 1	[7]
A204	DMF1LYP	Hepatitis B virus infection	1E51.0	Phase 1	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis B virus Capsid protein (HBV C)	TTM42UJ	CAPSD_HBVD3	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04398134) A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Assembly Biosciences.
• [3] JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 2020 Aug;159(2):521-533.e9.
• [4] Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166.
• [5] Clinical pipeline report, company report or official report of Enanta Pharmaceuticals.
• [6] Clinical pipeline report, company report or official report of Roche.
• [7] Clinical pipeline report, company report or official report of Shanghai Zhimeng Biopharma.
• [8] Clinical pipeline report, company report or official report of Klus Pharma